Posted on June 21st, 2021. Posted by ICR Westwicke
There’s a saying in investor relations: “You date your investment bankers, but you marry your research analysts.” Essentially, this means that a sell side analyst who covers your company will remain your partner for the long run. Investment bankers, on the other hand, work with a long list of companies and deal with jam-packed, demanding schedules. They don’t disappear after the initial public offering (IPO), but the time they can devote to your company diminishes.
Continue Reading
Posted on May 20th, 2021. Posted by ICR Westwicke
Special purpose acquisition company (SPAC) activity has exploded in the past two years, from 59 transactions in 2019, to 248 deals in 2020, to 308 SPACs so far in 2021. However, SPACs are not new. This type of transaction has been around for decades, continually evolving as it rises and falls in popularity.
Continue Reading
Posted on April 22nd, 2021. Posted by ICR Westwicke
Unlike quiet periods following an IPO, which are closely regulated by the Securities and Exchange Commission (SEC), end-of-quarter quiet periods are more loosely defined and not strictly regulated.
Continue Reading
Posted on March 4th, 2021. Posted by ICR Westwicke
One of our clients, a recently public diagnostics company, settled an ongoing royalty dispute with a major pharmaceutical company. The settlement amount was significantly lower than what our client had accrued, resulting in nearly $750 thousand upside to their P&L in the upcoming quarter.
Continue Reading
Posted on February 23rd, 2021. Posted by ICR Westwicke
No one would argue that 2020 was unique and challenging for almost every industry, including healthcare. The year forced both public and private companies to reconsider many aspects of how they do business and communicate with the investment community. As we all adapted and learned, our Westwicke blog covered a variety of investor relations topics, both pandemic related and not. Below are some of the most popular blog posts we published this year.
Continue Reading
Posted on January 27th, 2021. Posted by ICR Westwicke
The 2021 Westwicke / ICR Conference went virtual this year — and like many in-person events suddenly turned remote, attendees found new and unexpected opportunities for connecting with each other. Namely, the ability, finally, to be in two meetings at once.
Continue Reading
Posted on December 17th, 2020. Posted by ICR Westwicke
No one could have predicted the events of 2020. However, given the strength and evolution of the healthcare and biotech industry over the past 12 months, the team at Westwicke has some ideas about how the upcoming year may unfold. Below, we provide insight into what the new year may bring.
Continue Reading
Posted on October 30th, 2020. Posted by ICR Westwicke
In the wake of the coronavirus pandemic, the IPO market may never look the same. The swift shift to virtual roadshows, for example, has demonstrated efficiencies that are likely to make digital alternatives stick even after regular business travel resumes. But beyond the operational changes behind preparing a company to go public, the market has seen growing interest in alternatives to the IPO itself.
Continue Reading
Posted on October 21st, 2020. Posted by ICR Westwicke
As life science and medical device companies seek regulatory approval for their products, they will likely encounter difficult disclosure decisions around clinical and regulatory events. Clinical trial data and milestones can present great opportunities as well as significant challenges.
Continue Reading
Posted on September 25th, 2020. Posted by ICR Westwicke
Over the past several months, interest in special purpose acquisition companies (SPACs) has grown exponentially. SPAC transactions serve as an alternative to traditional IPOs, and while they have existed for many years, they are currently experiencing a resurgence within several industries.
Continue Reading
